BETP, a positive allosteric modulator of GLP-1R, a class B GPCR and an important therapeutic target for type II diabetes, covalently modifies two cysteine residues at the receptor's cytoplasmic face, where one of these enhances agonist-induced signaling. [In the version of the Table of Contents initially published, the labels for the BETP conditions were swapped in graphical abstract of the Nolte et al. article. The error has been corrected in the HTML and PDF versions of the Table of Contents.]
- Whitney M Nolte
- Jean-Philippe Fortin
- Philip A Carpino
